Regeneron Pharmaceuticals, Inc. (REGN)
| Market Cap | 76.89B |
| Revenue (ttm) | 13.85B |
| Net Income (ttm) | 4.65B |
| Shares Out | 107.59M |
| EPS (ttm) | 40.43 |
| PE Ratio | 17.68 |
| Forward PE | 14.89 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 905,578 |
| Open | 735.21 |
| Previous Close | 740.01 |
| Day's Range | 712.83 - 744.66 |
| 52-Week Range | 712.83 - 1,211.20 |
| Beta | 0.08 |
| Analysts | Buy |
| Price Target | 1,054.00 (+47.49%) |
| Earnings Date | Jan 31, 2025 |
About REGN
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq... [Read more]
Financial Performance
In 2023, Regeneron Pharmaceuticals's revenue was $13.12 billion, an increase of 7.76% compared to the previous year's $12.17 billion. Earnings were $3.95 billion, a decrease of -8.87%.
Financial StatementsAnalyst Forecast
According to 24 analysts, the average rating for REGN stock is "Buy." The 12-month stock price forecast is $1,054.0, which is an increase of 47.49% from the latest price.
News
Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results
Investigational REGN7508 (catalytic domain) and REGN9933 (A2 domain) are being evaluated for their potential to control thrombosis while minimizing bleeding risk in a variety of patient populations an...
Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
TARRYTOWN, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January ...
Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year
TARRYTOWN, N.Y., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced its sixth consecutive inclusion in the Dow Jones Sustainability World Index (DJSI Worl...
Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma
Odronextamab monotherapy led to complete responses in all patients with previously untreated follicular lymphoma evaluable for efficacy, per initial results from the safety lead-in portion of the conf...
Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab
Head-to-head exploratory cohort of a Phase 3 trial showed first-in-class poze-cemdi combination treatment helped patients achieve and maintain greater disease control, as measured by lactate dehydroge...
Regeneron Pharmaceuticals, Inc. (REGN) Piper Sandler 36th Annual Healthcare Conference (Transcript)
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Piper Sandler 36th Annual Healthcare Conference Call December 5, 2024 9:30 AM ET Company Participants Ryan Crowe - Senior Vice President, Investor Relati...
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
LOS ANGELES, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Regeneron Pharmaceuticals, ...
Medigene Receives Milestone Payment from Regeneron Pharmaceuticals, Inc.
Planegg/Martinsried, December 3, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)...
The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
LOS ANGELES , Dec. 2, 2024 /PRNewswire/ -- The Law Offices of Frank R. Cruz continues its investigation of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) on behalf of in...
Regeneron Pharmaceuticals, Inc. (REGN) Jefferies London Healthcare Conference (Transcript)
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) 2024 Jefferies London Healthcare Conference November 19, 2024 6:00 AM ET Company Participants Ryan Crowe - SVP, IR and Strategic Analysis Marion McCourt ...
Regeneron: The Biotech Stock To Buy Now
Biotech stocks, including Regeneron, have seen significant declines due to regulatory and political uncertainty, presenting a potential buying opportunity as seller exhaustion nears. Regeneron's 40% d...
Final Trades: Berkshire Hathaway, Regeneron, DocuSign and Leidos Holdings
The Investment Committee give you their top stocks to watch for the second half.
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria
Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More...
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antih...
Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH
Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria
Regeneron Announces Investor Conference Presentations
TARRYTOWN, N.Y., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up to one...
Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis Approval based on phase 3 data showing significantly more children aged one to 11 years on D...
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Regeneron Pharmac...
Regeneron: Buying A Promising Pipeline At A Fair Price (Rating Upgrade)
Regeneron shares fell 9.2% after the Q3 2024 report, making the company's valuation more attractive. The strong report was the 15th of 16 in the last four years to beat expectations. Investors were sp...
Regeneron: Investors In Panic Mode On Increased Eylea Fears
Shares of Regeneron are in free fall after recent litigation setbacks on Eylea and with Amgen launching a biosimilar low-dose version of Eylea. Investors may be overestimating the negative impact of t...
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2024 Earnings Call Transcript
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Ryan Crowe - SVP, IR and Strategic Analysis Leonard Schleifer - Board C...
Regeneron beats results estimates on demand for eczema treatment, eye drug
U.S. drugmaker Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter profit and revenue on Thursday, driven by strong demand for its eczema treatment Dupixent and blockbuster eye dise...
Regeneron Reports Third Quarter 2024 Financial and Operating Results
TARRYTOWN, N.Y., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2024 and provided a business update.
Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI
Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease status Confirmatory data to support U.S. regulatory resubmission by year-end; if a...